Phillips Medisize Highlights Inhaled Drug Delivery Device Platforms and Scientific Insights at DDL 2025
Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, will showcase its inhaled drug delivery device and formulation platforms and capabilities at the Drug Delivery to the Lungs conference (DDL 2025) in Edinburgh, Scotland, December 10–12. The company will also share insights through a podium presentation and multiple poster sessions.
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines.
Phillips Medisize Announces Scientific Presentations and Engagements at Respiratory Drug Delivery Conference, Highlighting Its Expanded Inhalation Drug Delivery Capabilities
Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced scientific presentations and engagements at the Respiratory Drug Delivery (RDD) conference in Lisbon, Portugal, May 6–9, 2025. The company’s experts will lead a panel discussion, sponsored workshop and several poster presentations that highlight innovations and developments in inhalation product development.
